Dicerna Pharmaceuticals Inc (DRNA) - Financial Analysis Review - GlobalData - Company Reports

Dicerna Pharmaceuticals Inc (DRNA) - Financial Analysis Review

Dicerna Pharmaceuticals Inc (DRNA) - Financial Analysis Review - GlobalData - Company Reports
Dicerna Pharmaceuticals Inc (DRNA) - Financial Analysis Review
Published Nov 29, 2016
44 pages — Published Nov 29, 2016
Price US$ 125.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that offers discovery and development of innovative treatments. The company discovers and develops treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Its product pipeline is being generated from the companys proprietary RNA interference. Dicernas product pipeline comprises DCR-PH1, KRAS Program, primary hyperoxaluria 1 and hepatocellular carcinoma. The company provides RNAi-targeted drugs, delivery systems and DsiRNA molecules. It also offers traditional therapeutic modalities, such as small molecules and monoclonal antibodies.

GlobalData's Dicerna Pharmaceuticals Inc (DRNA) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.

Dicerna Pharmaceuticals Inc Key Recent Developments:

Nov 07,2016: Dicerna Reports Third Quarter 2016 Financial and Operational Results
Sep 26,2016: Dicerna Prioritizes Resources to Advance GalXC Product Candidates
Aug 04,2016: Dicerna Reports Second Quarter 2016 Financial and Operational Results
Jun 29,2016: New Preclinical Data Show Potential of Dicerna GalXC Subcutaneous Delivery Platform as RNAi Drug Discovery Engine
Jun 15,2016: Dicerna Appoints Martin Freed, M.D., to Board of Directors


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

  
Source:
Document ID
GDPH93530FA
Country
Industry
Ticker
Company
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Section 1 - About the Company41
Dicerna Pharmaceuticals Inc - Key Facts51
Dicerna Pharmaceuticals Inc - Key Employees61
Dicerna Pharmaceuticals Inc - Major Products and Services71
Dicerna Pharmaceuticals Inc - Pharmaceutical Pipeline Products Data83
  Dicerna Pharmaceuticals Inc, Pipeline Products by Therapy Area81
  Dicerna Pharmaceuticals Inc, Pipeline Products by Development Phase92
Dicerna Pharmaceuticals Inc - History111
Dicerna Pharmaceuticals Inc - Locations And Subsidiaries121
  Head Office121
Section 2 Company Analysis131
Company Overview131
Dicerna Pharmaceuticals Inc - Key Competitors141
Section 3 Company Financial Ratios151
Financial Ratios - Capital Market Ratios151
Financial Ratios - Annual Ratios162
Performance Chart181
Financial Performance181
Financial Ratios - Interim Ratios191
Financial Ratios - Ratio Charts201
Section 4 Company s Lifesciences Financial Deals and Alliances212
  Dicerna Pharmaceuticals Inc, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 2016211
  Dicerna Pharmaceuticals Inc, Pharmaceuticals &Healthcare, Deals By Type, 2010 to YTD 2016221
Dicerna Pharmaceuticals Inc, Recent Deals Summary231
Section 5 Company s Recent Developments241
Nov 07, 2016: Dicerna Reports Third Quarter 2016 Financial and Operational Results242
Sep 26, 2016: Dicerna Prioritizes Resources to Advance GalXC Product Candidates262
Aug 04, 2016: Dicerna Reports Second Quarter 2016 Financial and Operational Results283
Jun 29, 2016: New Preclinical Data Show Potential of Dicerna GalXC Subcutaneous Delivery Platform as RNAi Drug Discovery Engine311
Jun 15, 2016: Dicerna Appoints Martin Freed, M.D., to Board of Directors321
May 09, 2016: Dicerna Reports First Quarter 2016 Financial and Operational Results332
Apr 18, 2016: Dicerna Announces Appointment of John "Jack" Green as Chief Financial Officer351
Mar 10, 2016: Dicerna Announces Fourth Quarter and Full Year 2015 Financial and Operational Results362
Dec 16, 2015: Dicerna Announces Addition to NASDAQ Biotechnology Index381
Dec 15, 2015: Dicerna Pharmaceuticals Appoints John "Jack" Green Interim Chief Financial Officer391
Section 6 Appendix405
  Methodology401
  Ratio Definitions404
  About GlobalData441
  Contact Us441
  Disclaimer441

Table Of Contents

GlobalData - Company Reports—GlobalData is an industry analysis specialist, providing business information products and services. These high quality company reports are created via a large research and analysis capability, drawing from extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
GlobalData - Company Reports. "Dicerna Pharmaceuticals Inc (DRNA) - Financial Analysis Review" Nov 29, 2016. Alacra Store. Sep 20, 2019. <http://www.alacrastore.com/storecontent/GlobalData-Company-Reports/Dicerna-Pharmaceuticals-Inc-DRNA-Financial-Analysis-Review-2087-63304>
  
APA:
GlobalData - Company Reports. (2016). Dicerna Pharmaceuticals Inc (DRNA) - Financial Analysis Review Nov 29, 2016. New York, NY: Alacra Store. Retrieved Sep 20, 2019 from <http://www.alacrastore.com/storecontent/GlobalData-Company-Reports/Dicerna-Pharmaceuticals-Inc-DRNA-Financial-Analysis-Review-2087-63304>
  
US$ 125.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Company Profiles from one place.